India Thrombus Treatment Market Research Report By Type (Atrial Thrombus, Venous Thrombus) and By Treatment (Medical Therapy, Surgery, Others)- Forecast to 2035

India Thrombus Treatment Market Overview

As per MRFR analysis, the India Thrombus Treatment Market Size was estimated at 1.58 (USD Billion) in 2023.The India Thrombus Treatment Market is expected to grow from 1.61(USD Billion) in 2024 to 6.42 (USD Billion) by 2035. The India Thrombus Treatment Market CAGR (growth rate) is expected to be around 13.394% during the forecast period (2025 - 2035).

Key India Thrombus Treatment Market Trends Highlighted

The rising incidence of thromboembolic illnesses is driving significant developments in the India thrombus treatment market. The prevalence of thrombus-related disorders has increased in the population because to the growth in lifestyle-related health problems like diabetes and obesity.

Early identification and diagnosis have increased as a result of the government's emphasis on improved healthcare services and awareness-raising, which encourages people to seek treatment sooner.

Furthermore, because they offer efficient treatments with fewer side effects, developments in medical technology and therapeutic approaches—such as the creation of innovative anticoagulants and minimally invasive surgical techniques—act as significant market drivers.

The expansion of healthcare infrastructure and the availability of cutting-edge medical facilities in both urban and rural areas are driving additional growth in the India Thrombus Treatment Market. To improve patient outcomes, efforts must be made to improve healthcare personnel' training on thrombus prevention and management.

Furthermore, there is a lot of emphasis on research and development to provide novel treatments that target thrombus formation. This creates opportunities for cooperation between the public and private sectors and promotes improvements in treatment alternatives.

The treatment of thrombus has recently moved toward personalized medicine as medical professionals try to customize treatments according to the unique characteristics of each patient. Better management of thromboembolic disorders is now possible due to the increased accessibility of consultations and follow-up care brought about by the growing use of telemedicine, particularly in the wake of the pandemic.

Additionally, the number of collaborations between pharmaceutical companies and healthcare providers to provide improved disease management solutions is increasing in the Indian healthcare sector. This all-encompassing strategy for treating thrombus-related illnesses demonstrates how the Indian thrombus treatment market is developing due to both innovation and a patient-centered approach.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

India Thrombus Treatment Market Drivers

Increasing Prevalence of Cardiovascular Diseases

The rise in cardiovascular diseases in India is a significant driver for the India Thrombus Treatment Market. According to the Indian Heart Association, there has been a noticeable increase in cardiovascular conditions, with around 30% of deaths in India attributed to heart diseases in recent years.

With an aging population and lifestyle changes leading to obesity and diabetes, the number of patients requiring thrombus treatment is expected to rise.

This trend is further supported by organizations such as the Ministry of Health and Family Welfare, indicating that the burden of heart diseases is likely to continue to escalate. As healthcare infrastructure improves, the demand for effective thrombus treatments will likely increase, contributing to market growth.

Advancements in Medical Technology

Innovations in medical technology are accelerating the development of new thrombus treatment options in the India Thrombus Treatment Market. For instance, the growth of minimally invasive procedures and advanced imaging technologies has made thrombus management more efficient and safer.

The Indian government’s initiatives to promote research and development in the healthcare sector are resulting in new treatment modalities. The Digital India campaign also supports technology adoption in healthcare, which has the potential to decrease hospital stay durations and improve patient outcomes, ultimately driving market growth for thrombus treatments.

Rise in Geriatric Population

India is witnessing a demographic shift with a growing geriatric population, leading to an increased incidence of thrombotic disorders. The Ministry of Statistics and Programme Implementation noted that the population aged 60 and above accounted for approximately 8% in 2021, which is projected to rise to 20% by 2050.

This demographic is more susceptible to thrombus-related conditions such as strokes and deep vein thrombosis. As healthcare services expand to accommodate this age group, the demand for effective and comprehensive thrombus treatment options will likely surge, driving the India Thrombus Treatment Market significantly.

Government Initiatives and Health Insurance Coverage

Government initiatives to enhance health insurance coverage are bolstering access to thrombus treatments. The Ayushman Bharat scheme, which aims to provide affordable healthcare to a large section of the population, is a notable example. According to recent updates from the National Health Authority, over 10 million individuals have been treated under this scheme since its launch.

This increased access to health services leads to higher demand for thrombus treatments, thereby fueling growth in the India Thrombus Treatment Market. Additionally, private insurance companies are also expanding their coverage to include newer thrombus treatment options, enhancing patient reach.

India Thrombus Treatment Market Segment Insights

Thrombus Treatment Market Type Insights

The India Thrombus Treatment Market is largely categorized by type, which includes Atrial Thrombus and Venous Thrombus. This market classification plays a crucial role in understanding the specific treatment needs and approaches for various thrombotic conditions prevalent in the country.

Atrial Thrombus is often associated with conditions like atrial fibrillation, where blood clots form in the heart chambers, leading to significant risks, including stroke. The growing awareness of early detection and effective management of this condition has raised the demand for specialized thrombus treatments in India in recent years.

On the other hand, Venous Thrombus encompasses a broader array of ailments such as deep vein thrombosis and pulmonary embolism, which are caused by blood clots in the veins. This segment holds a major share due to the rising incidence of sedentary lifestyles and obesity among the Indian population, highlighting the need for preventive measures and tailored treatment options.

Both Atrial and Venous Thrombus segments represent significant areas of growth within the India Thrombus Treatment Market, driven by increasing healthcare expenditure, advancements in medical technologies, and a better understanding of thrombotic disorders.

Furthermore, the integration of digital health solutions and telemedicine is expected to bolster patient engagement and thus improve treatment outcomes for both types of thrombolytic stages, reflecting a trend towards personalized medicine in the Indian healthcare landscape.

Alongside that, government initiatives aimed at improving cardiovascular health through awareness programs and public health campaigns are likely to further support the expansion of the Atrial and Venous Thrombus segments in the market, ensuring that necessary care reaches those who need it most.

This indicates a focused strategy to address the rising incidence of thrombotic conditions and underscores the importance of differentiated treatment approaches based on type within India's broader healthcare strategy.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Thrombus Treatment Market Treatment Insights

The India Thrombus Treatment Market within the Treatment segment is witnessing notable growth driven by increasing incidences of thrombotic disorders, heightened awareness regarding the importance of timely interventions, and advancements in treatment methodologies.

Medical Therapy, which encompasses pharmacological interventions, is particularly significant as it addresses both prevention and management of thrombus-related complications, often dominating treatment protocols due to its non-invasive nature and accessibility.

Surgery plays a critical role in cases where therapeutic options are insufficient, offering solutions for more complex thrombus formations that require physical removal, thus enhancing patient outcomes. Additionally, the segment identified as Others includes various emerging non-conventional treatments and technologies that cater to patient-specific needs.

This segment is witnessing innovation, which is expected to substantially influence the market landscape. As healthcare infrastructure in India continues to improve and government initiatives emphasize advanced treatment options, the Treatment segment is positioned for steady growth overall, contributing significantly to the evolving dynamics of the India Thrombus Treatment Market revenue.

India Thrombus Treatment Market Key Players and Competitive Insights

The India Thrombus Treatment Market has been experiencing significant transformation due to advancements in technology and a rising awareness concerning thrombotic diseases. The competitive landscape in this market is characterized by a range of key players who are focused on the development and introduction of innovative treatment options to satisfy the increasing demand.

The growing incidences of thromboembolic disorders, along with an aging population, are further propelling the market. Players in this sector are engaging in extensive research and development initiatives to enhance their product offerings.

Furthermore, strategic collaborations, partnerships, and investments in clinical trials are being highlighted by companies aiming to secure a stronger foothold in the Indian market. This competitive environment is crucial for understanding market dynamics and the future trajectory of thrombus treatments in India.

Bristol-Myers Squibb operates in the India Thrombus Treatment Market with a strong portfolio of anticoagulants and thrombolytic therapies that address various aspects of thrombus management. The company has built a considerable presence in India, leveraging its global expertise and innovative product lines to enhance patient outcomes.

Its robust research capabilities contribute to the development of new treatment modalities tailored for the Indian demographic, positioning Bristol-Myers Squibb as a formidable player in the market. The company's commitment to ongoing clinical research and collaborations with healthcare professionals strengthens its reputation, allowing it to address unmet needs effectively.

Bristol-Myers Squibb's well-established distribution networks enable efficient product delivery, thereby ensuring that patients have timely access to critical therapies.

Boston Scientific has carved a notable position in the India Thrombus Treatment Market through its advanced medical devices and therapies aimed at thromboembolic complications. The company offers a variety of innovative products including mechanical thrombectomy devices and catheters, which are essential for effective thrombus removal procedures.

Boston Scientific's strong market presence in India is underpinned by its strategic approach to addressing local patient needs, thus ensuring that its solutions are both relevant and effective. The company has a track record of successful mergers and acquisitions that have bolstered its capabilities in research and development, enhancing the overall efficacy of its product range.

Boston Scientific is focused on advancing technologies and solutions that not only improve patient outcomes but also streamline clinical workflows, solidifying its competitive edge in the Indian market for thrombus treatments.

Key Companies in the India Thrombus Treatment Market Include:

• Bristol-Myers Squibb


• Boston Scientific


• Abbott


• Terumo


• Bayer


• Roche


• Stryker


• Johnson & Johnson


• GSK


• Medtronic


• AstraZeneca


• Miltenyi Biotec


• Sanofi


• Novartis


• Cardinal Health

India Thrombus Treatment Market Developments

In recent months, the India Thrombus Treatment Market has experienced significant developments, particularly with the increasing focus on innovative treatment solutions and the rising prevalence of thromboembolic disorders.

In September 2023, Bristol-Myers Squibb announced the successful completion of its clinical trials for a new anticoagulant medication, aiming to reduce the risk of thrombosis in patients. Additionally, in August 2023, Boston Scientific launched its latest endovascular therapy device, enhancing treatment options for various thrombus-related conditions in the Indian market.

The market has also seen a notable growth in the valuation of companies such as Medtronic and Abbott, driven by advancements in research and technology. Several companies are collaborating with Indian healthcare institutions to enhance patient access to thrombus treatment, reflecting a commitment to improving healthcare outcomes.

Moreover, there was a significant acquisition in July 2023 when Terumo acquired a local company specializing in thrombus treatment delivery systems, which is anticipated to strengthen its operational capabilities in India.

Overall, innovations and strategic partnerships are setting a positive trajectory for the India Thrombus Treatment Market, driven by increasing healthcare demands and an emphasis on advanced treatment modalities.

India Thrombus Treatment Market Segmentation Insights

Thrombus Treatment Market Type Outlook

• Atrial Thrombus


• Venous Thrombus

Thrombus Treatment Market Treatment Outlook

• Medical Therapy


• Surgery


• Others

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	1.58(USD Billion)
MARKET SIZE 2024	1.61(USD Billion)
MARKET SIZE 2035	6.42(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	13.394% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	BristolMyers Squibb, Boston Scientific, Abbott, Terumo, Bayer, Roche, Stryker, Johnson & Johnson, GSK, Medtronic, AstraZeneca, Miltenyi Biotec, Sanofi, Novartis, Cardinal Health
SEGMENTS COVERED	Type, Treatment
KEY MARKET OPPORTUNITIES	Rising prevalence of thrombotic disorders, Growing demand for advanced therapeutic solutions, Increased investment in healthcare infrastructure, Expansion of specialized medical training programs, Adoption of telemedicine for remote consultations
KEY MARKET DYNAMICS	Rising prevalence of thrombus cases, Increasing adoption of minimally invasive procedures, Advancements in thrombus management devices, Growing awareness of cardiovascular diseases, Supportive government initiatives and funding
COUNTRIES COVERED	India